论文部分内容阅读
目的:探讨大黄虫丸对肝癌介入治疗后所致肝纤维化相关指标的影响。方法:将40例因肝癌施行经导管化疗栓塞后致肝纤维化的患者分成观察组和对照组,对照组予常规抗纤维化治疗,观察组在对照组基础上加服大黄虫丸,观察治疗前后患者血清肝纤维化指标的改善情况。结果:与治疗前比较,观察组治疗后血清纤维化指标透明质酸(HA)明显降低,差异有统计学意义(P<0.05);层粘蛋白(LN)、肝胆酸(CG)、三型前胶原肽(PCⅢ)无明显升高或降低。对照组治疗后HA,LN,CG,PCⅢ均升高(P<0.05);两组治疗后HA,LN,PCⅢ,CG等4项指标差异均有统计学意义(P<0.05)。结论:大黄虫丸对肝癌患者介入治疗后所致的肝纤维化有一定的改善作用。
Objective: To investigate the effects of Dahuang Zhechong Pill on liver fibrosis related indicators after liver cancer interventional therapy. Methods: Forty patients with hepatic fibrosis after transcatheter arterial chemoembolization due to liver cancer were divided into observation group and control group. The control group was given conventional anti-fibrosis treatment. The observation group was treated with Dahuang Zhechong pills on the basis of the control group, Before and after the improvement of serum liver fibrosis indicators. Results: Compared with the pretreatment group, the serum fibrosis index (HA) in the observation group was significantly lower after treatment (P <0.05); the levels of laminin, CG, Procollagen peptide (PC Ⅲ) no significant increase or decrease. The levels of HA, LN, CG and PCIII in the control group were significantly increased after treatment (P <0.05). There were significant differences in HA, LN, PC Ⅲ and CG between the two groups after treatment (P <0.05). Conclusion: Dahuang Shechong Pills can improve hepatic fibrosis after interventional therapy in patients with liver cancer.